ESMO Open最新文献

{"title":"MAP 2024 Officers and Organisation","authors":"","doi":"10.1016/S2059-7029(24)01725-3","DOIUrl":"10.1016/S2059-7029(24)01725-3","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103955"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142525796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tislelizumab plus chemotherapy as first-line treatment of locally advanced or metastatic nonsquamous non-small-cell lung cancer (final analysis of RATIONALE-304: a randomized phase III trial)","authors":"S. Lu ,&nbsp;J. Wang ,&nbsp;Y. Yu ,&nbsp;X. Yu ,&nbsp;Y. Hu ,&nbsp;Z. Ma ,&nbsp;X. Li ,&nbsp;W. He ,&nbsp;Y. Bao ,&nbsp;M. Wang","doi":"10.1016/j.esmoop.2024.103728","DOIUrl":"10.1016/j.esmoop.2024.103728","url":null,"abstract":"<div><h3>Background</h3><div>The purpose of this study was to report an updated, final analysis with longer follow-up for the open-label phase III RATIONALE-304 study of first-line tislelizumab plus chemotherapy versus chemotherapy alone for advanced nonsquamous non-small-cell lung cancer (nsq-NSCLC).</div></div><div><h3>Materials and methods</h3><div>Patients with histologically confirmed stage IIIB/IV nsq-NSCLC were randomized (2 : 1) to 4-6 cycles of tislelizumab plus platinum-based chemotherapy and pemetrexed every 3 weeks, followed by maintenance tislelizumab and pemetrexed, or platinum-based chemotherapy and pemetrexed alone every 3 weeks followed by maintenance pemetrexed. The primary endpoint was independent review committee (IRC)-assessed progression-free survival (PFS_IRC). Overall survival (OS), safety, and tolerability were secondary endpoints.</div></div><div><h3>Results</h3><div>Overall, 334 patients were randomized (tislelizumab plus chemotherapy: <em>n</em> = 223; chemotherapy: <em>n</em> = 111). At final analysis (median follow-up 16.1 months), safety/tolerability profiles in both arms were consistent with the interim analysis. Tislelizumab plus chemotherapy continued to demonstrate prolongation of PFS_IRC versus chemotherapy alone {stratified hazard ratio (HR) 0.63 [95% confidence interval (CI) 0.47-0.86]; median PFS_IRC 9.8 months (95% CI 8.9-11.7 months) versus 7.6 months (95% CI 5.6-8.0 months), respectively}. OS stratified HR for tislelizumab plus chemotherapy versus chemotherapy was 0.90 (95% CI 0.63-1.28), with median OS of 21.4 months (95% CI 17.7 months-not estimable) versus 21.3 months (95% CI 15.6 months-not estimable), respectively. At a subsequent <em>ad hoc</em> analysis (median follow-up 19.3 months), OS HR between arms was 0.85 (95% CI 0.63-1.14); when adjusted for crossover using the two-stage method, the OS HR was 0.68 (95% CI 0.48-0.96).</div></div><div><h3>Conclusions</h3><div>After longer follow-up, first-line tislelizumab plus chemotherapy continued to demonstrate a manageable safety profile and a favorable PFS benefit over chemotherapy alone in patients with advanced/metastatic nsq-NSCLC.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 10","pages":"Article 103728"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142497418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuroendocrine neoplasms of head and neck, genitourinary and gynaecological systems, unknown primaries, parathyroid carcinomas and intrathyroid thymic neoplasms: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆","authors":"J. Hadoux ,&nbsp;A. Lamarca ,&nbsp;E. Grande ,&nbsp;D. Deandreis ,&nbsp;G. Kaltsas ,&nbsp;E.T. Janson ,&nbsp;B. Tombal ,&nbsp;M. Pavel ,&nbsp;J. Thariat ,&nbsp;M.F. van Velthuysen ,&nbsp;P. Herman ,&nbsp;C. Dromain ,&nbsp;E. Baudin ,&nbsp;A. Berruti ,&nbsp;ESMO Guidelines Committee","doi":"10.1016/j.esmoop.2024.103664","DOIUrl":"10.1016/j.esmoop.2024.103664","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 10","pages":"Article 103664"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142497405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"30P Role of suppressor of cytokine signalling 6 (SOCS6) in colorectal cancer pathogenesis: Integrating clinical and molecular perspectives","authors":"A.K. Al-Bahri ,&nbsp;A. Al Kharusi ,&nbsp;F. Al Zadjali","doi":"10.1016/j.esmoop.2024.103776","DOIUrl":"10.1016/j.esmoop.2024.103776","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103776"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142526640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"23P Unraveling predictive transcriptomic signatures of anti-EGFR therapy response in RAS/BRAF wild-type metastatic colorectal cancer","authors":"A.R. de Abreu ,&nbsp;L. van Kempen ,&nbsp;M. Peeters ,&nbsp;G. van Camp ,&nbsp;K. Op de Beeck","doi":"10.1016/j.esmoop.2024.103769","DOIUrl":"10.1016/j.esmoop.2024.103769","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103769"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142525910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"43P Assessment of methylation-specific genetic markers for reliable colorectal cancer detection and their potential in liquid biopsy applications","authors":"J. Dvorak,&nbsp;M. Krausová,&nbsp;N. Hajkova,&nbsp;J. Hojný","doi":"10.1016/j.esmoop.2024.103789","DOIUrl":"10.1016/j.esmoop.2024.103789","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103789"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142531063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"82P Applying computational approaches to build a predictive protein structure and discover novel inhibitors for mitotic serine/threonine kinase BUB1B","authors":"J. Glenny Pescov ,&nbsp;M.J. Martinez ,&nbsp;S. Schurer","doi":"10.1016/j.esmoop.2024.103823","DOIUrl":"10.1016/j.esmoop.2024.103823","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103823"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142526201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"44P Calculated numerical karyotype with ultra low-coverage whole genome sequencing undercovers recurrent chromosomal aberrations in resectable colorectal cancer","authors":"T.S. Tarawneh,&nbsp;I. Karim,&nbsp;P. Ross,&nbsp;A. Burchert,&nbsp;A. Neubauer,&nbsp;E. Mack","doi":"10.1016/j.esmoop.2024.103790","DOIUrl":"10.1016/j.esmoop.2024.103790","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103790"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142526559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"8P Precision medicine drug testing platform to guide the treatment of EML4-ALK fusion lung cancers","authors":"S.D. Merajver ,&nbsp;A. Udager ,&nbsp;A. Qin ,&nbsp;L. Bao ,&nbsp;X. Cheng ,&nbsp;H. Madhi ,&nbsp;L. Goo ,&nbsp;V. Kathawate ,&nbsp;P. Ulintz ,&nbsp;A. Liu ,&nbsp;H. Serhan ,&nbsp;V. Navani ,&nbsp;J. Jefferies ,&nbsp;M.S. Ali ,&nbsp;M. Monument ,&nbsp;J. Kratz ,&nbsp;A. Smith ,&nbsp;M. Soellner ,&nbsp;N. Merrill","doi":"10.1016/j.esmoop.2024.103754","DOIUrl":"10.1016/j.esmoop.2024.103754","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103754"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142531577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Volumetric measurement to evaluate treatment response to induction chemotherapy on MRI outperformed RECIST guideline in outcome prediction in advanced nasopharyngeal carcinoma","authors":"T.S.A. Kwong ,&nbsp;H.S. Leung ,&nbsp;F.K.F. Mo ,&nbsp;Y.M. Tsang ,&nbsp;L. Lan ,&nbsp;L.M. Wong ,&nbsp;T.Y. So ,&nbsp;E.P. Hui ,&nbsp;B.B.Y. Ma ,&nbsp;A.D. King ,&nbsp;Q.Y.H. Ai","doi":"10.1016/j.esmoop.2024.103933","DOIUrl":"10.1016/j.esmoop.2024.103933","url":null,"abstract":"<div><h3>Background</h3><div>Treatment response evaluated by tumour size change is an important indicator for outcome prediction. Advanced nasopharyngeal carcinoma (adNPC) grows irregularly, and so the unidimensional measurement may not be accurately applied to adNPC for outcome prediction. This study aimed to evaluate values of unidimensional and volumetric measurements for treatment response to induction chemotherapy (IC) for outcome prediction in adNPC and compared the values with that of RECIST 1.1 guideline.</div></div><div><h3>Materials and methods</h3><div>Pre-treatment and post-IC magnetic resonance images (MRIs) from 124 patients with stage III-IVA NPC were retrospectively reviewed. Sums of the maximum unidimensional diameters (D) and volumes of the targeted tumours (primary tumour and two largest metastatic lymph nodes) on the pre- (D_pre and V_pre) and post-IC MRIs (D_post-IC and V_post-IC) and percentage changes in D (Δ D%) and V (ΔV%) between two scans were calculated and correlated with disease-free survival (DFS), locoregional recurrence-free survival (LRRFS), and distant metastases-free survival (DMFS) using Cox regression analysis. Area under the curves (AUCs) of independent measurements and RECIST groups (RECIST response and non-response groups) for predicting disease recurrence, locoregional recurrence, and distant metastases, respectively, were calculated and compared using the DeLong test.</div></div><div><h3>Results</h3><div>Univariable analysis showed correlations between high D_post-IC with poor DFS and DMFS (<em>P</em> &lt; 0.05), but not with LRRFS (<em>P</em> = 0.07); high V_post-IC and low ΔV% (less decrease in volume on post-IC) with poor DFS, LRRFS, and DMFS (<em>P</em> &lt; 0.05); and no correlations between D_pre, ΔD%, and V_pre and the outcomes (<em>P</em> &gt; 0.05). Multivariable analysis showed that ΔV% was the only independent measurement for outcomes (<em>P</em> &lt; 0.05). Compared with RECIST groups, ΔV% of 47.9% (median value) showed a higher AUC for disease recurrence (0.682 versus 0.526, <em>P</em> &lt; 0.01) and for locoregional recurrence (0.782 versus 0.585, <em>P</em> &lt; 0.01), but not for distant metastases (0.593 versus 0.518, <em>P</em> = 0.26).</div></div><div><h3>Conclusions</h3><div>Volumetric measurement to evaluate treatment response to IC outperformed unidimensional measurement and RECIST guideline in outcome prediction in adNPC.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 10","pages":"Article 103933"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142379243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}